Aortic Valve StenosisNCT05956652
Hydra Registry - Italy Experience
An observational study of Aortic Valve Stenosis, run by Sahajanand Medical Technologies Limited at 4 sites in Italy.
Trial summary
Hydra-IT is a multicenter observational study aim to collect clinical, procedural and follow-up data and evaluate the short, medium and long term results of Hydra TAVI System in patient with severe aortic stenosis. Read more about this study
- Who is it for?
- Ages 18 to 99 years
- Conditions the study is for
- Aortic Valve Stenosis
- What is being tested?
- Hydra Transcatheter Aortic Valve System
- Type of treatment
- Medical device
- How many people
- 0 participants
- Where
- 4 sitesItaly
- Study dates
- 1 Jul 2023to 31 Jul 2029
- How long will I take part?
- 5 Years
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 99 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patient with severe aortic valve stenosis
Who may be able to join
- Patients with severe symptomatic native aortic valve stenosis and candidates for the TAVI procedure based on the evaluation of the Heart Team
- Ability to understand and provide informed consent for inclusion in the study
Who cannot join
- Contraindication to TAVI: e.g. evidence of intracardiac mass, thrombus or vegetation, endocarditis.
- Refusal by the patient to participate in the study
- High probability of non-adherence to required follow-ups
Trial locations and contacts
4 sites in 1 country.
Italy4 sites
Fondazione Poliambulanza Istituto
Brescia, 25124
Montevergine Clinic, Mercogliano, Italy
Mercogliano, 83013
IRCCS Ospedale Galeazzi-Sant'Ambrogio
Milan, 20157
Università degli studi di Padova
Padova, 35122
About this study
Official title: Observational Study on the Efficacy and Safety of Transcatheter Implantation of Hydra Biological Aortic Prosthesis
Hydra-IT is a multicenter observational study aim to collect clinical, procedural and follow-up data and evaluate the short, medium and long term results of Hydra TAVI System in patient with severe aortic stenosis.
Read the detailed description
Hydra-IT is a multicenter observational study conducted across different centres in Italy. The primary objective of the study is to evaluate the safety and efficacy of transcatheter aortic valve implantation and clinical outcome in patients treated with Hydra device. Secondary objective is to evaluate the long term (up to 5 years) effectiveness and the quality of treatment using Hydra device. Patients with severe stenosis symptomatic of the native aortic valve or bioprosthesis in a degenerated aortic position will be included in this study.
- Conditions
- Aortic Valve Stenosis
- Being tested
- Hydra Transcatheter Aortic Valve System
- Keywords
- Aortic Valve Stenosis, TAVI, Hydra
- Medical subject headings
- Aortic Valve Stenosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Hydra Transcatheter Aortic Valve SystemDevice
The Hydra device is self-expanding transcatheter aortic valve consists of a self-expanding nitinol frame and three bovine pericardial leaflets in supra-annular position.
What is being measured
The primary outcome is the main question the study is designed to answer.
Cardiovascular mortality
Measured: 30 days
Secondary outcomes (12)
All-cause mortality
Cardiovascular mortality, valve-related mortality, and non-cardiovascular mortality
Measured: 30 days, 6 months, 1 year, 2 years, 3 years, 4 years, 5 years
All stroke
Disabling and non-disabling stroke
Measured: 30 days, 6 months, 1 year, 2 years, 3 years, 4 years, 5 years
Disabling stroke
Measured: 30 days, 6 months, 1 year, 2 years, 3 years, 4 years, 5 years
Myocardial infarction
Measured: 30 days, 6 months, 1 year, 2 years, 3 years, 4 years, 5 years
Life-threatening or disabling bleeding
Measured: 30 days
Major vascular complications
Measured: 30 days
Acute kidney injury (Stage 2 or 3)
Measured: 30 days
New permanent pacemaker implantation (PPM)
Measured: 30 days, 6 months, 1 year, 2 years, 3 years, 4 years, 5 years
Paravalvular Leak (PVL)
Measured: 30 days, 6 months, 1 year, 2 years, 3 years, 4 years, 5 years
Effective Orifice Area (EOA)
Measured: 30 days, 6 months, 1 year, 2 years, 3 years, 4 years, 5 years
Mean aortic valve gradient
Measured: 30 days, 6 months, 1 year, 2 years, 3 years, 4 years, 5 years
New York Heart Association (NYHA) functional classification
Measured: 30 days, 6 months, 1 year, 2 years, 3 years, 4 years, 5 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Jul 2023
- Study start1 Jul 2023
- Primary completion31 Jul 2027 (estimated)
- Study completion31 Jul 2029 (estimated)
Why it stopped: Withdrawn (No Participants Enrolled)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Aortic Valve StenosisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 0 participants (actual)
- Target duration
- 5 Years
Sponsor and investigators
- Lead sponsor
- Sahajanand Medical Technologies Limited
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Clinica Di Montevergine
- Responsible party
- Sponsor
- Investigators
- Dr. Angelo Cioppa, Principal investigator, Montevergine Clinic, Mercogliano, Italy
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05956652
- Sponsor's protocol ID
- Hydra-IT, V1.0, 02/03/2022
- Status last verified
- Aug 2026
- First submitted
- 14 Jul 2023
- Last updated
- 18 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 18 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Observational Study on the Efficacy and Safety of Transcatheter Implantation of Hydra Biological Aortic Prosthesis
- ClinicalTrials.gov ID
- NCT05956652
- Acronym / sponsor ID
- Hydra-IT, V1.0, 02/03/2022
- Conditions
- Aortic Valve Stenosis
- Keywords
- Aortic Valve Stenosis, TAVI, Hydra
- Study type
- Observational
- Recruitment status
- WithdrawnReason stopped: Withdrawn (No Participants Enrolled)
- Enrolment
- 0 participants (actual)
- Lead sponsor
- Sahajanand Medical Technologies LimitedIndustry (pharma, biotech, devices)
- Collaborators
- Clinica Di Montevergine
- Study start
- 1 Jul 2023 (actual)
- Primary completion
- 31 Jul 2027 (estimated)
- Study completion
- 31 Jul 2029 (estimated)
- First posted
- 21 Jul 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Hydra-IT is a multicenter observational study aim to collect clinical, procedural and follow-up data and evaluate the short, medium and long term results of Hydra TAVI System in patient with severe aortic stenosis.
Detailed description
Hydra-IT is a multicenter observational study conducted across different centres in Italy. The primary objective of the study is to evaluate the safety and efficacy of transcatheter aortic valve implantation and clinical outcome in patients treated with Hydra device. Secondary objective is to evaluate the long term (up to 5 years) effectiveness and the quality of treatment using Hydra device. Patients with severe stenosis symptomatic of the native aortic valve or bioprosthesis in a degenerated aortic position will be included in this study.
Study design
- Observational model
- Case only
- Time perspective
- Prospective
- Target follow-up
- 5 Years
Who may qualify
- Ages
- 18 to 99 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patient with severe aortic valve stenosis
Key inclusion criteria (2 listed)
- Patients with severe symptomatic native aortic valve stenosis and candidates for the TAVI procedure based on the evaluation of the Heart Team
- Ability to understand and provide informed consent for inclusion in the study
Key exclusion criteria (3 listed)
- Contraindication to TAVI: e.g. evidence of intracardiac mass, thrombus or vegetation, endocarditis.
- Refusal by the patient to participate in the study
- High probability of non-adherence to required follow-ups
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Hydra Transcatheter Aortic Valve SystemThe Hydra device is self-expanding transcatheter aortic valve consists of a self-expanding nitinol frame and three bovine pericardial leaflets in supra-annular position. | Device | – |
Primary outcome
Cardiovascular mortality
Time frame: 30 days
12 secondary outcomes
All-cause mortality
Time frame: 30 days, 6 months, 1 year, 2 years, 3 years, 4 years, 5 years
All stroke
Time frame: 30 days, 6 months, 1 year, 2 years, 3 years, 4 years, 5 years
Disabling stroke
Time frame: 30 days, 6 months, 1 year, 2 years, 3 years, 4 years, 5 years
Myocardial infarction
Time frame: 30 days, 6 months, 1 year, 2 years, 3 years, 4 years, 5 years
Life-threatening or disabling bleeding
Time frame: 30 days
Major vascular complications
Time frame: 30 days
Acute kidney injury (Stage 2 or 3)
Time frame: 30 days
New permanent pacemaker implantation (PPM)
Time frame: 30 days, 6 months, 1 year, 2 years, 3 years, 4 years, 5 years
Paravalvular Leak (PVL)
Time frame: 30 days, 6 months, 1 year, 2 years, 3 years, 4 years, 5 years
Effective Orifice Area (EOA)
Time frame: 30 days, 6 months, 1 year, 2 years, 3 years, 4 years, 5 years
Mean aortic valve gradient
Time frame: 30 days, 6 months, 1 year, 2 years, 3 years, 4 years, 5 years
New York Heart Association (NYHA) functional classification
Time frame: 30 days, 6 months, 1 year, 2 years, 3 years, 4 years, 5 years
Results and safety
The study was withdrawn before enrolling participants, so there are no results.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Aug 2026.
- Individual participant dataSharing planned: No
Related trials for Aortic Valve Stenosis
Active, not recruitingObservational study
REdo Transcatheter Aortic VALVE Implantation for the Management of Transcatheter Aortic Valve Failure
Aortic Valve Stenosis
Not yet recruiting
NHLBI SESAME (SEptal Scoring Along Midline Endocardium) Multi-Center Prospective Study Using Improvised Off-Label Devices
Hypertrophic Cardiomyopathy, Left Ventricular Outflow Obstruction
Not yet recruiting
Exercise and Diet Supplements for Older Patients Undergoing TAVI: the IRON-TAVI Trial
Aortic Stenosis Disease, Aortic Stenosis Symptomatic
Not yet recruiting
A Clinical Trial to Evaluate the Effects of the NeuEve Dryness Treatment Kit on Vaginal Health, Comfort, and Quality of Life in Postmenopausal Women
Relieves Vaginal Dryness / Improves Self-Lubrication, Improves Strength & Elasticity of Vagina (Aka Collagen and Elastin)
RecruitingPhase 2
A Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy
Non-obstructive Hypertrophic Cardiomyopathy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Dr. Angelo Cioppa principal investigator
Montevergine Clinic, Mercogliano, Italy
4 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Aortic Valve Stenosis, run by Sahajanand Medical Technologies Limited at 4 sites in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: withdrawn, as of the sponsor's last update on 18 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 4 sites in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was withdrawn before enrolling participants, so there are no results.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Cardiovascular mortality (time frame: 30 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Aug 2026.